NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NHGRI E-185-2014-0-US-12 VIRAL GENE THERAPY AS TREATMENT FOR CHOLESTEROL STORAGE DISEASE OR DISORDER US DIV 17/033,166 Pending
NHLBI E-076-2021-0-US-03 Systems And Methods For Applying Pressure To A Bodily Organ US ORD 17/032,283 Pending
NCI E-100-2018-0-US-04 3-O-SULFO-GALACTOSYLCERAMIDE ANALOGS AS ACTIVATORS OF TYPE II NKT CELLS AND USES THEREOF US National Stage 17/041,604 Pending
NIAAA E-049-2016-0-US-01 COMPOUND FOR USE IN PROTECTING SKIN US CON 17/032,616 Pending
NHLBI E-076-2021-0-PCT-02 Systems And Methods For Applying Pressure To A Bodily Organ PCT PCT PCT/US2020/052690 Expired
NCI E-097-2018-0-EA-07 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES EA National Stage 202092044 Pending
NCI E-211-2020-0-US-01 PLK1 POLO BOX DOMAIN INHIBITOR AND METHOD OF TREATING CANCER US 63/082,813 Abandoned
NCI E-176-2014-0-MX-56 Anti-Human Papillomavirus 16 E7 T Cell Receptors MX DIV MX/a/2020/010035 Pending
NCI E-113-2018-0-US-08 COMBINATION OF NEAR INFRARED PHTOIMMUNOTHERAPY TARGETING CANCER CELLS AND HOST-IMMUNE ACTIVATION US National Stage 17/040,426 Issued
NIAID E-052-2017-4-EP-50 Trispecific And/or Trivalent Binding Proteins For Prevention Or Treatment Of HIV Infection EP DIV 20197556.2 Pending
NCI E-042-2014-0-EP-25 Chimeric Antigen Receptors Targeting CD-19 EP DIV 20197459.9 Pending
NIMH E-345-2013-0-US-08 Monitoring The Effects Of Sleep Deprivation Using Neuronal Avalanches US CON 17/028,901 Abandoned
NCATS E-133-2020-0-US-01 METHODS AND SYSTEMS FOR EVAPORATION OF SOLVENTS US 63/081,723 Abandoned
NCI E-209-2014-0-US-18 PHOTO-CONTROLLED REMOVAL OF TARGETS IN VITRO AND IN VIVO US CON 17/026,724 11781955 Issued PDF
NIDA E-017-2018-0-US-04 Novel Biased Potent Opioid-like Agonists As Improved Medications To Treat Chronic And Acute Pain US National Stage 16/982,196 11352365 Issued PDF
NCI E-168-2018-0-PCT-02 METHODS OF ISOLATING T CELL POPULATIONS PCT PCT PCT/US2020/051548 Expired
NCI E-168-2018-0-EP-04 METHODS OF ISOLATING T CELL POPULATIONS EP National Stage 20786149.3 Pending
NIAID E-131-2020-4-US-01 Anti-Coronavirus Antibodies And Methods Of Use US 63/080,351 Abandoned
NIDCR E-107-2022-0-US-01 Methods Of Dosing Triphenyl Calcilytic Compounds US 63/080,165 Abandoned
NHGRI E-167-2020-0-US-01 Novel Adeno-associated Viral (AAV) Vectors To Treat Hereditary Methylmalonic Acidemia (MMA) Caused By Methylmalonyl-coA Mutase (MMUT) Deficiency US 63/080,337 Abandoned
NHGRI E-044-2013-1-US-18 OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA US CON 17/024,100 11802283 Issued PDF
NCI E-176-2022-0-PC-01 Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease PCT PCT PCT/EP2020/075948 Expired
NCI E-176-2022-0-US-02 Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease US National Stage 17/753,706 Pending
NCI E-176-2022-0-EP-01 Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease EP National Stage 20774960.7 Pending
NCI E-176-2022-0-HK-01 Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease HK EP 62023066863.9 Pending
NCI E-176-2022-0-KR-01 Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease KR National Stage 10-2022-7008878 Pending
NCI E-176-2022-0-JP-01 Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease JP National Stage 2022-517823 Pending
NCI E-176-2022-0-IL-01 Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease IL National Stage 1991-09-29 Pending
NCI E-176-2022-0-CN-01 Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease CN National Stage 202080065098.2 Pending
NCI E-036-2021-0-US-01 METHODS FOR TREATING INFECTIONS US 63/079,741 Abandoned
NCI E-176-2022-0-AU-01 Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease AU National Stage 2020349353 Pending
NCI E-176-2022-0-BR-01 Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease BR National Stage BR112022004861 Pending
NCI E-494-2013-0-AU-22 Methods of Preparing Anti-human Papillomavirus Antigen T Cells AU DIV 2020233702 Issued
NEI E-058-2018-0-US-03 Using Machine Learning And/or Neural Networks To Validate Stem Cells And Their Derivatives (2-D Cells And 3-D Tissues) For Use In Cell Therapy And Tissue Engineered Products US National Stage 16/981,531 11531844 Issued PDF
NEI E-058-2018-0-AU-04 USING MACHINE LEARNING AND/OR NEURAL NETWORKS TO
VALIDATE STEM CELLS AND THEIR DERIVATIVES FOR USE IN CELL
THERAPY, DRUG DISCOVERY, AND DIAGNOSTICS 		AU National Stage 2019236297 Pending
NINDS E-025-2018-1-EP-02 Positive Allosteric Modulators of Dopamine 1 Receptor and Methods of Use Thereof EP National Stage 19716018.7 Issued
NINDS E-025-2018-1-DE-01 Positive Allosteric Modulators of Dopamine 1 Receptor and Methods of Use Thereof DE EP 19716018.7 Issued
NINDS E-025-2018-1-FR-01 Positive Allosteric Modulators of Dopamine 1 Receptor and Methods of Use Thereof FR EP 19716018.7 Issued
NINDS E-025-2018-1-CH-01 Positive Allosteric Modulators of Dopamine 1 Receptor and Methods of Use Thereof CH EP 19716018.7 Issued
NINDS E-025-2018-1-GB-01 Positive Allosteric Modulators of Dopamine 1 Receptor and Methods of Use Thereof GB EP 19716018.7 Issued
NINDS E-025-2018-1-IE-01 Positive Allosteric Modulators of Dopamine 1 Receptor and Methods of Use Thereof IE EP 19716018.7 Issued
NIAID E-166-2021-0-US-01 Coronavirus Antibodies And Uses Thereof US 63/078,666 Abandoned
NCI E-036-2018-0-KR-04 HEPTAMETHINE CYANINES FOR USE AS FLUORESCENT MARKERS OF THE BILIARY AND RENAL SYSTEMS KR National Stage 2020-7026443 Abandoned
NCI E-097-2018-0-SA-14 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES SA National Stage 520420134 Pending
NCI E-097-2018-0-AE-03 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES AE National Stage P6001291/2020 Pending
NHLBI E-143-2021-1-US-01 TISSUE EXCISION, CUTTING, AND REMOVAL SYSTEMS AND METHODS US 63/077,579 Abandoned
NHGRI E-122-2017-0-PCT-02 CANCER DETECTION AND CLASSIFICATION PCT PCT PCT/US2020/050522 Expired
NCI E-182-2019-2-PCT-01 RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER PCT PCT COMB PCT/US2020/050439 Expired
NCI E-097-2018-0-US-16 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES US National Stage 16/980,205 Pending
NCI E-182-2019-2-EP-05 RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER EP National Stage 20785624.6 Pending